Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Danielle Brill
TRU
Danielle Brill
Wall Street Analyst
★★★☆☆
#1740
on 13Foresight · ranked by our own returns
51%
Success Rate
-1.4%
Average Return
21 of 41 calls profitable · -8.2% vs benchmark
📈 Across the calls we could measure, roughly 51% of Danielle Brill's ratings turned a profit when each position was held for 1 year — averaging -1.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

132 Buy 23 Hold 0 Sell
Danielle's Stock Coverage 38 ratings · 2026-06-19
Company Date Position Consensus Price Target 1-Yr Return
IRON
Disc Medicine
Jun 16, 2026 BUY Strong Buy
+20.3% avg upside
21 analysts
·
DNTH
Dianthus Therapeutics
Jun 15, 2026 BUY Strong Buy
+8.9% avg upside
29 analysts
-4.4%
ARGX
Argenx Se
Jun 09, 2026 BUY Strong Buy
-15.8% avg upside
46 analysts
-0.2%
CLYM
Climb Bio
Jun 02, 2026 BUY Strong Buy
+57.9% avg upside
18 analysts
·
PRAX
Praxis Precision Medicines
Jun 02, 2026 BUY Strong Buy
+92.1% avg upside
24 analysts
$616.00
118.14% Upside
+4.6%
APGE
Apogee Therapeutics
May 28, 2026 HOLD Strong Buy
+28.7% avg upside
19 analysts
$81.00
10.46% Downside
+13.6%
VRTX
Vertex Pharmaceuticals
May 27, 2026 BUY Strong Buy
-2.7% avg upside
61 analysts
$542.00
20.04% Upside
+5.0%
IMVT
Immunovant
May 22, 2026 HOLD Strong Buy
+9.0% avg upside
24 analysts
$30.00
15.05% Downside
+1.6%
PVLA
Palvella Therapeutics
May 21, 2026 BUY Strong Buy
+45.4% avg upside
27 analysts
-2.4%
RAPP
Rapport Therapeutics, Inc.
May 19, 2026 BUY Strong Buy
+46.2% avg upside
12 analysts
$56.00
49.96% Upside
+7.3%
WVE
Wave Life Sciences
May 19, 2026 BUY Strong Buy
+261.8% avg upside
28 analysts
+0.3%
INSM
Insmed
May 18, 2026 BUY Strong Buy
+82.1% avg upside
36 analysts
$185.00
93.10% Upside
-8.1%
BIIB
Biogen
May 15, 2026 HOLD Strong Buy
+25.1% avg upside
51 analysts
+3.0%
MAZE
Maze Therapeutics, Inc.
May 14, 2026 BUY Strong Buy
+145.3% avg upside
12 analysts
-6.0%
UPB
Upstream Bio, Inc.
May 14, 2026 BUY Strong Buy
+514.9% avg upside
9 analysts
$43.00
588.00% Upside
-26.6%
TECX
Tectonic Therapeutic
May 11, 2026 BUY Strong Buy
+88.0% avg upside
24 analysts
$60.00
99.96% Upside
+1.3%
BBIO
BridgeBio Pharma
May 11, 2026 BUY Strong Buy
+38.3% avg upside
34 analysts
$102.00
53.96% Upside
+4.2%
HRMY
Harmony Biosciences Holdings
May 08, 2026 HOLD Strong Buy
+39.5% avg upside
13 analysts
$29.00
12.87% Downside
-2.9%
NBIX
Neurocrine
May 07, 2026 BUY Strong Buy
+7.8% avg upside
37 analysts
$155.00
2.05% Downside
+6.8%
ALNY
Alnylam Pharma
May 01, 2026 BUY Strong Buy
+23.4% avg upside
51 analysts
-4.5%
CNTA
Centessa Pharmaceuticals
Apr 12, 2026 HOLD Buy
-14.4% avg upside
19 analysts
$38.00
5.05% Downside
+0.7%
QURE
uniQure
Dec 10, 2024 BUY Strong Buy
+16.1% avg upside
29 analysts
$8.98
80.68% Downside
+31.6%
RGNX
RegenXBio
Nov 18, 2024 BUY Strong Buy
+381.2% avg upside
22 analysts
$18.00
130.82% Upside
+10.8%
PTCT
PTC Therapeutics
Oct 10, 2024 HOLD Buy
-1.4% avg upside
29 analysts
+72.1%
SRPT
Sarepta Therapeutics
Oct 10, 2024 BUY Buy
+246.5% avg upside
49 analysts
$150.00
755.72% Upside
-81.9%
ACAD
ACADIA Pharmaceuticals
Oct 10, 2024 HOLD Strong Buy
+66.0% avg upside
42 analysts
+37.9%
BMRN
BioMarin Pharmaceutical
Oct 10, 2024 BUY Strong Buy
+72.7% avg upside
52 analysts
$79.00
44.40% Upside
-25.1%
DNLI
Denali Therapeutics
Oct 10, 2024 HOLD Strong Buy
+60.2% avg upside
24 analysts
-40.3%
XENE
Xenon
Oct 10, 2024 BUY Strong Buy
+19.0% avg upside
28 analysts
$50.00
5.58% Downside
-1.9%
AGIO
Agios Pharma
Oct 10, 2024 BUY Strong Buy
+73.8% avg upside
29 analysts
$51.00
49.22% Upside
-2.9%
KYNB
Kyntra Bio
Jun 26, 2023 HOLD Buy
+369.6% avg upside
14 analysts
-61.1%
PASG
Passage Bio
May 16, 2022 BUY Buy
+214.0% avg upside
14 analysts
$10.00
78.81% Upside
-40.8%
VERX
Vertex
Jun 30, 2021 HOLD Buy
+224.5% avg upside
22 analysts
-48.4%
KROS
Keros Therapeutics
May 27, 2020 BUY Strong Buy
+139.8% avg upside
21 analysts
$45.00
322.50% Upside
+86.0%
ALKS
Alkermes
Feb 13, 2020 HOLD Strong Buy
-17.5% avg upside
34 analysts
+14.6%
AXSM
Axsome Therapeutics
Dec 16, 2019 BUY Strong Buy
-10.5% avg upside
28 analysts
$125.00
50.05% Downside
+0.8%
CBIO
Crescent Biopharma
Nov 07, 2019 HOLD Strong Buy
+26.4% avg upside
17 analysts
$5.00
71.67% Downside
·
GILD
Gilead Sciences
Jul 26, 2016 HOLD Strong Buy
-4.8% avg upside
66 analysts
-5.9%
🔒 33 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Danielle Brill — Frequently Asked Questions
How accurate are Danielle Brill's stock ratings?
Based on the calls 13Foresight could measure, about 51% of Danielle's ratings were profitable over a one-year hold, with an average return of -1.4% per rating, or -8.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Danielle ranked on 13Foresight?
Danielle Brill is currently ranked #1740 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Danielle cover?
Danielle most recently has ratings on IRON, DNTH, ARGX, CLYM, PRAX, APGE, VRTX, IMVT, PVLA, RAPP, WVE, INSM and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.